Portage Biotech (NASDAQ: PRTG) is a clinical-stage immuno-oncology company advancing multi-targeted therapies with the mission to expand the number of patients who derive long-term benefit from immunotherapy through its pipeline of first-in-class/best-in-class product candidates. Lead programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. Our unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products, bolstered by proven practices from drug discovery veterans and a strong industry network. The result is a viable product development strategy that supports commercial potential and company growth.
Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. Portage executes the development process and creates strategies to guide novel immuno-oncology assets as single agents and in combinations, from bench through human proof of concept. Our team of scientists, clinicians and pharma-experienced executives have a long history of success, collectively contributing to ten oncology drug approvals and creating high-value exits. We reduce the risks associated with early clinical development through more efficient capital management and scientific oversight, and our fail-fast approach enables us to continuously review hundreds of assets and asset combinations, selecting only the most promising to advance.
To learn more about Portage, download fact sheet.
